Meeting
2014 ASCO Annual Meeting
A phase II cluster study of single agent AUY922, BYL719, INC280, LDK378, and MEK162 in Chinese patients with advanced non-small cell lung cancer (NSCLC).
Authors
Qing Zhou
Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China
Qing Zhou , Xu-Chao Zhang , Bin Peng , Xiaolu Yu , Mikhail Akimov , Barbara Lynn Weber , Yi-Long Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS8122)
DOI
10.1200/jco.2014.32.15_suppl.tps8122
Abstract #
TPS8122
Poster Bd #
301A
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Real-world (rw) analysis of quantitative MET copy number (CN) as a biomarker in NSCLC.
First Author: David Chun Cheong Tsui
Poster
2021 ASCO Annual Meeting
A large real-world study on the effectiveness of the combined inhibition of EGFR and MET in EGFR-mutant advanced non-small cell lung cancer (NSCLC).
First Author: Liu Li
Poster
2019 ASCO Annual Meeting
The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.
First Author: Kiyotaka Yoh
Poster
2015 ASCO Annual Meeting
Nationwide genomic screening network for the development of novel targeted therapies in advanced non-small cell lung cancer (LC-SCRUM-Japan).
First Author: Shingo Matsumoto